GGrantIndex
← Leaderboards

Ernst John Schaefer

Tufts Medical Center

$8,539,085
Attributed
$8,539,085
Total exposure
7
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200512
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12

Funding mix

By agency

NIH$8,539,085 · 7

By mechanism

R01$6,740,312 · 3
P50$1,743,105 · 1
M01$55,668 · 3

Top collaborators

No co-investigators on record.

Most similar at Tufts Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchCoronary DisorderCholesterolHigh Density LipoproteinsHuman SubjectHuman Therapy EvaluationDisease /Disorder Proneness /RiskGenotypePostmenopauseObesityBody WeightStatistics /BiometryTriglyceridesFibratesMetabolic SyndromePlasmaInflammationLipidsBlood Lipoprotein MetabolismAllelesCentral ObesityDiabetes MellitusApolipoproteinsGene Frequency

Grant awards (25)

Core--Laboratory and Data Management$594,659
P50 · FY2012 · HL · contact PI
Core--Laboratory and Data Management$369,637
P50 · FY2011 · HL · contact PI
Molecular Basis of High Density Lipoprotein Deficiency$333,571
R01 · FY2009 · HL · contact PI
Core--Laboratory and Data Management$568,520
P50 · FY2008 · HL · contact PI
Molecular Basis of High Density Lipoprotein Deficiency$338,168
R01 · FY2008 · HL · contact PI
Molecular Basis of High Density Lipoprotein Deficiency$327,849
R01 · FY2007 · HL · contact PI
Pharmacogenetics of the Statin Response$817,001
R01 · FY2006 · HL · contact PI
Molecular Basis of High Density Lipoprotein Deficiency$314,593
R01 · FY2006 · HL · contact PI
Core--Laboratory and Data Management$210,289
P50 · FY2006 · HL · contact PI
Pharmacogenetics of the Statin Response$836,840
R01 · FY2005 · HL
Molecular Basis of High Density Lipoprotein Deficiency$316,952
R01 · FY2005 · HL
EFFECTS OF EXTENDED-RELEASE NIACIN ON A COMBINATION OF LOVASTATIN$7,735
M01 · FY2005 · RR
Pharmacogenetics of the Statin Response$791,279
R01 · FY2004 · HL
Effects of Atorvastatin on the Kinetics of APO B-100$4,675
M01 · FY2004 · RR
Effects of Extended-Release Niacin on a Combination$519
M01 · FY2004 · RR
Pharmacogenetics of the Statin Response$702,973
R01 · FY2003 · HL
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK$176,259
R01 · FY2003 · HL
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK$418,861
R01 · FY2002 · HL
MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS$0
M01 · FY2002 · RR
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK$406,663
R01 · FY2001 · HL
MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY$285,300
R01 · FY2001 · HL
MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS$0
M01 · FY2001 · RR
DIETARY COMPOSITION, OBESITY, AND CARDIOVASCULAR RISK$394,819
R01 · FY2000 · HL
MOLECULAR BASIS OF HIGH DENSITY LIPOPROTEIN DEFICIENCY$279,184
R01 · FY2000 · HL
MECHANISM OF INCREASED PLASMA APO A1 LEVELS BY ESTROGENS$42,739
M01 · FY2000 · RR